This company has been marked as potentially delisted and may not be actively trading. GlycoMimetics (GLYC) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock GlycoMimetics (NASDAQ:GLYC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.70%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$3.54MNumber OfInsiders Selling(Last 3 Years)3Amount OfInsider Selling(Last 3 Years)$3.06M Get GLYC Insider Trade Alerts Want to know when executives and insiders are buying or selling GlycoMimetics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLYC Insider Buying and Selling by Quarter GlycoMimetics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/7/2024Public Equities L.P. InvusMajor ShareholderSell614$18.00$11,052.00 8/5/2024Public Equities L.P. InvusMajor ShareholderSell1,645$19.00$31,255.00 8/1/2024Public Equities L.P. InvusMajor ShareholderSell635$22.00$13,970.00 7/29/2024Public Equities L.P. InvusMajor ShareholderSell3,639$24.00$87,336.00 7/26/2024Public Equities L.P. InvusMajor ShareholderSell2,583$24.00$61,992.00 6/20/2024Edwin RockInsiderBuy1,900$25.00$47,500.00 9/21/2023Edwin RockInsiderBuy350$138.00$48,300.00 5/17/2023Brian M HahnCFOSell37$195.00$7,215.00 5/10/2023Daniel M JuniusDirectorBuy300$156.00$46,800.00 5/8/2023Bruce S JohnsonSVPBuy135$157.00$21,195.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/23/2023Public Equities L.P. InvusMajor ShareholderBuy2,000$175.00$350,000.00 2/21/2023Public Equities L.P. InvusMajor ShareholderBuy500$185.00$92,500.00 2/17/2023Public Equities L.P. InvusMajor ShareholderBuy2,000$171.00$342,000.00 2/15/2023Public Equities L.P. InvusMajor ShareholderBuy10,000$216.00$2,160,000.00 2/9/2023Public Equities L.P. InvusMajor ShareholderBuy114$324.00$36,936.00 1/25/2023Scott D SandellMajor ShareholderSell6,520$326.00$2,125,520.00 1/5/2023Scott D SandellMajor ShareholderSell713$276.00$196,788.00 1/3/2023Scott D SandellMajor ShareholderSell1,748$299.00$522,652.00 12/22/2022Edwin RockInsiderBuy1,100$225.00$247,500.00 11/14/2022Edwin RockInsiderBuy1,000$143.00$143,000.00 (Data available from 1/1/2013 forward) GLYC Insider Trading Activity - Frequently Asked Questions Who is on GlycoMimetics' Insider Roster? The list of insiders at GlycoMimetics includes Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, Public Equities L.P. Invus, and Scott D Sandell. Learn more on insiders at GLYC. What percentage of GlycoMimetics stock is owned by insiders? 8.70% of GlycoMimetics stock is owned by insiders. Learn more on GLYC's insider holdings. Which GlycoMimetics insiders have been buying company stock? The following insider purchased GLYC shares in the last 24 months: Edwin Rock ($95,800.00). How much insider buying is happening at GlycoMimetics? Insiders have purchased a total of 2,250 GLYC shares in the last 24 months for a total of $95,800.00 bought. Which GlycoMimetics insiders have been selling company stock? The following insider sold GLYC shares in the last 24 months: Public Equities L.P. Invus ($205,605.00). How much insider selling is happening at GlycoMimetics? Insiders have sold a total of 9,116 GlycoMimetics shares in the last 24 months for a total of $205,605.00 sold. GlycoMimetics Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Compensation: $1.13MMs. Rachel K. King (Age 65)Co-Founder & Director Compensation: $40kMr. Brian M. Hahn (Age 50)Senior VP & CFO Compensation: $822.12kDr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Compensation: $677.4kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical Operations More Insider Trading Tools from MarketBeat Related Companies Hyperion DeFi Insider Trades Renovaro Insider Trades Mersana Therapeutics Insider Trades Exicure Insider Trades OnKure Therapeutics Insider Trades Medicus Pharma Insider Trades Xilio Therapeutics Insider Trades Mural Oncology Insider Trades Reviva Pharmaceuticals Insider Trades SCYNEXIS Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Loop Industries Insiders Buy Stock, Signal Confidence in OutlookDueling Insider Moves: Heavy Buying Here, Big Selling ThereCostco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks This page (NASDAQ:GLYC) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
